Skip to main content
    • Aa
    • Aa

Chemical and pharmacological chaperones as new therapeutic agents

  • Tip W. Loo (a1) and David M. Clarke (a1)

Proteins that are exported from the cell, or targeted to the cell surface or other organelles, are synthesised and assembled in the endoplasmic reticulum and then delivered to their destinations. Point mutations – the most common cause of human genetic diseases – can inhibit folding and assembly of the protein in the endoplasmic reticulum. The unstable or partially folded mutant protein does not undergo trafficking and is usually rapidly degraded. A potential therapy for protein misfolding is to correct defective protein folding and trafficking using pharmacological chaperones. Pharmacological chaperones are substrates or modulators that appear to function by directly binding to the partially folded biosynthetic intermediate to stabilise the protein and allow it to complete the folding process to yield a functional protein. Initial clinical studies with pharmacological chaperones have successfully reduced clinical symptoms of disease. Therefore, pharmacological chaperones show great promise as a new class of therapeutic agents that can be specifically tailored for a particular genetic disease.

Corresponding author
*Corresponding author: David M. Clarke, Department of Medicine, University of Toronto, Rm 7342, Medical Sciences Building, 1 King's College Circle, Toronto, Ontario, M5S 1A8, Canada. Tel/Fax: +1 416 978 1105; E-mail:
Linked references
Hide All

This list contains references from the content that can be linked to their source. For a full set of references and notes please see the PDF or HTML where available.

2 P.D. Stenson (2003) Human Gene Mutation Database (HGMD): 2003 update. Hum Mutat 21, 577-581

3 P.C. Ng and S. Henikoff (2006) Predicting the effects of amino acid substitutions on protein function. Annu Rev Genomics Hum Genet 7, 61-80

4 D.N. Hebert , S.C. Garman and M. Molinari (2005) The glycan code of the endoplasmic reticulum: asparagine-linked carbohydrates as protein maturation and quality-control tags. Trends Cell Biol 15, 364-370

5 R.R. Kopito (1997) ER quality control: the cytoplasmic connection. Cell 88, 427-430

6 L. Pedrola (2005) GDAP1, the protein causing Charcot-Marie-Tooth disease type 4A, is expressed in neurons and is associated with mitochondria. Hum Mol Genet 14, 1087-1094

7 Y. Sekijima (2005) The biological and chemical basis for tissue-selective amyloid disease. Cell 121, 73-85

8 M. Schroder and R.J. Kaufman (2005) The mammalian unfolded protein response. Annu Rev Biochem 74, 739-789

9 B.R. Pearse and D.N. Hebert (2006) Cotranslocational degradation: utilitarianism in the ER stress response. Mol Cell 23, 773-775

10 A. Horwich (2002) Protein aggregation in disease: a role for folding intermediates forming specific multimeric interactions. J Clin Invest 110, 1221-1232

11 M. Stefani (2004) Protein misfolding and aggregation: new examples in medicine and biology of the dark side of the protein world. Biochim Biophys Acta 1739, 5-25

12 C. Soto , L. Estrada and J. Castilla (2006) Amyloids, prions and the inherent infectious nature of misfolded protein aggregates. Trends Biochem Sci 31, 150-155

14 M. Aridor and L.A. Hannan (2002) Traffic jams II: an update of diseases of intracellular transport. Traffic 3, 781-790

15 M. Aridor and W.E. Balch (1999) Integration of endoplasmic reticulum signaling in health and disease. Nat Med 5, 745-751

16 A. De Jaco (2006) A mutation linked with autism reveals a common mechanism of endoplasmic reticulum retention for the alpha,beta-hydrolase fold protein family. J Biol Chem 281, 9667-9676

17 F.S. Seibert (1997) Cystic fibrosis: channel, catalytic, and folding properties of the CFTR protein. J Bioenerg Biomembr 29, 429-442

18 U.E. Petaja-Repo (2000) Export from the endoplasmic reticulum represents the limiting step in the maturation and cell surface expression of the human delta opioid receptor. J Biol Chem 275, 13727-13736

19 H.L. Paulson (1991) Analysis of early events in acetylcholine receptor assembly. J Cell Biol 113, 1371-1384

20 J.A. Quilty , J. Li and R.A. Reithmeier (2002) Impaired trafficking of distal renal tubular acidosis mutants of the human kidney anion exchanger kAE1. Am J Physiol Renal Physiol 282, F810-820

21 J.A. Valentijn , G.K. Fyfe and C.M. Canessa (1998) Biosynthesis and processing of epithelial sodium channels in Xenopus oocytes. J Biol Chem 273, 30344-30351

22 T.W. Loo , M.C. Bartlett and D.M. Clarke (2002) Introduction of the most common cystic fibrosis mutation (Delta F508) into human P-glycoprotein disrupts packing of the transmembrane segments. J Biol Chem 277, 27585-27588

23 E.Y. Chen (2004) The ΔF508 mutation disrupts packing of the transmembrane segments of the cystic fibrosis transmembrane conductance regulator. J Biol Chem 279, 39620-39627

24 T. Arakawa (2006) Small molecule pharmacological chaperones: From thermodynamic stabilization to pharmaceutical drugs. Biochim Biophys Acta 1764, 1677-1687

25 E. Papp and P. Csermely (2006) Chemical chaperones: mechanisms of action and potential use. Handb Exp Pharmacol 405–416

26 K. Gekko and S.N. Timasheff (1981) Mechanism of protein stabilization by glycerol: preferential hydration in glycerol-water mixtures. Biochemistry 20, 4667-4676

28 S. Sato (1996) Glycerol reverses the misfolding phenotype of the most common cystic fibrosis mutation. J Biol Chem 271, 635-638

29 J.A. Burrows , L.K. Willis and D.H. Perlmutter (2000) Chemical chaperones mediate increased secretion of mutant alpha 1-antitrypsin (alpha 1-AT) Z: A potential pharmacological strategy for prevention of liver injury and emphysema in alpha 1-AT deficiency. Proc Natl Acad Sci U S A 97, 1796-1801

30 B.K. Tamarappoo and A.S. Verkman (1998) Defective aquaporin-2 trafficking in nephrogenic diabetes insipidus and correction by chemical chaperones. J Clin Invest 101, 2257-2267

31 C.M. Tan , H.H. Nickols and L.E. Limbird (2003) Appropriate polarization following pharmacological rescue of V2 vasopressin receptors encoded by X-linked nephrogenic diabetes insipidus alleles involves a conformation of the receptor that also attains mature glycosylation. J Biol Chem 278, 35678-35686

32 J.L. Song and D.T. Chuang (2001) Natural osmolyte trimethylamine N-oxide corrects assembly defects of mutant branched-chain alpha-ketoacid decarboxylase in maple syrup urine disease. J Biol Chem 276, 40241-40246

35 R.C. Rubenstein , M.E. Egan and P.L. Zeitlin (1997) In vitro pharmacologic restoration of CFTR-mediated chloride transport with sodium 4-phenylbutyrate in cystic fibrosis epithelial cells containing delta F508-CFTR. J Clin Invest 100, 2457-2465

37 K. Kubota (2006) Suppressive effects of 4-phenylbutyrate on the aggregation of Pael receptors and endoplasmic reticulum stress. J Neurochem 97, 1259-1268

38 U. Ozcan (2006) Chemical chaperones reduce ER stress and restore glucose homeostasis in a mouse model of type 2 diabetes. Science 313, 1137-1140

39 T.W. Loo and D.M. Clarke (1997) Correction of defective protein kinesis of human P-glycoprotein mutants by substrates and modulators. J Biol Chem 272, 709-712

40 M. Dean and T. Annilo (2005) Evolution of the ATP-binding cassette (ABC) transporter superfamily in vertebrates. Annu Rev Genomics Hum Genet 6, 123-142

41 T.W. Loo and D.M. Clarke (2005) Recent progress in understanding the mechanism of P-glycoprotein-mediated drug efflux. J Membr Biol 206, 173-185

43 T.W. Loo and D.M. Clarke (1998) Superfolding of the partially unfolded core-glycosylated intermediate of human P-glycoprotein into the mature enzyme is promoted by substrate- induced transmembrane domain interactions. J Biol Chem 273, 14671-14674

44 T.W. Loo and D.M. Clarke (1999) The transmembrane domains of the human multidrug resistance P-glycoprotein are sufficient to mediate drug binding and trafficking to the cell surface. J Biol Chem 274, 24759-24765

45 T.W. Loo , M.C. Bartlett and D.M. Clarke (2006) Insertion of an arginine residue into the transmembrane segments corrects protein misfolding. J Biol Chem 281, 29436-29440

46 S.M. Rowe , S. Miller and E.J. Sorscher (2005) Cystic fibrosis. N Engl J Med 352, 1992-2001

47 J.R. Riordan (1989) Identification of the cystic fibrosis gene: cloning and characterization of complementary DNA. Science 245, 1066-1073

48 S.H. Cheng (1990) Defective intracellular transport and processing of CFTR is the molecular basis of most cystic fibrosis. Cell 63, 827-834

49 Y. Yang (1993) The common variant of cystic fibrosis transmembrane conductance regulator is recognized by hsp70 and degraded in a pre-Golgi nonlysosomal compartment. Proc Natl Acad Sci U S A 90, 9480-9484

50 N. Kartner (1992) Mislocalization of delta F508 CFTR in cystic fibrosis sweat gland. Nat Genet 1, 321-327

51 M.L. Drumm (1990) Correction of the cystic fibrosis defect in vitro by retrovirus- mediated gene transfer [published erratum appears in Cell 1993 Jun 16;74(1):215]. Cell 62, 1227-1233

52 G.M. Denning (1992) Processing of mutant cystic fibrosis transmembrane conductance regulator is temperature-sensitive. Nature 358, 761-764

53 W. Dalemans (1991) Altered chloride ion channel kinetics associated with the delta F508 cystic fibrosis mutation. Nature 354, 526-528

54 F. Zhang , N. Kartner and G.L. Lukacs (1998) Limited proteolysis as a probe for arrested conformational maturation of delta F508 CFTR. Nat Struct Biol 5, 180-183

55 E.Y. Chen , M.C. Bartlett and D.M. Clarke (2000) Cystic fibrosis transmembrane conductance regulator has an altered structure when its maturation is inhibited. Biochemistry 39, 3797-3803

56 N. Pedemonte (2005) Small-molecule correctors of defective DeltaF508-CFTR cellular processing identified by high-throughput screening. J Clin Invest 115, 2564-2571

57 F. Van Goor (2006) Rescue of ΔF508 CFTR trafficking and gating in human cystic fibrosis airway primary cultures by small molecules. Am J Physiol Lung Cell Mol Physiol 290, L1117-1130

58 T.W. Loo , M.C. Bartlett and D.M. Clarke (2005) Rescue of ΔF508 and other misprocessed CFTR mutants by a novel quinazoline compound. Mol Pharm 2, 407-413

59 T.W. Loo (2006) The chemical chaperone CFcor-325 repairs folding defects in the transmembrane domains of CFTR processing mutants. Biochem J 395, 537-542

61 Y. Wang (2007) Modulating the folding of P-glycoprotein and cystic fibrosis transmembrane conductance regulator truncation mutants with pharmacological chaperones. Mol Pharmacol 71, 751-758

62 M.E. Egan (2004) Curcumin, a major constituent of turmeric, corrects cystic fibrosis defects. Science 304, 600-602

63 C. Norez (2006) Rescue of functional delF508-CFTR channels in cystic fibrosis epithelial cells by the alpha-glucosidase inhibitor miglustat. FEBS Lett 580, 2081-2086

64 M.E. Egan (2002) Calcium-pump inhibitors induce functional surface expression of Delta F508-CFTR protein in cystic fibrosis epithelial cells. Nat Med 8, 485-492

65 E. Cormet-Boyaka (2004) Rescuing cystic fibrosis transmembrane conductance regulator (CFTR)-processing mutants by transcomplementation. Proc Natl Acad Sci U S A 101, 8221-8226

66 L.G. Johnson (1992) Efficiency of gene transfer for restoration of normal airway epithelial function in cystic fibrosis. Nat Genet 2, 21-25

67 M. Sharma (2001) Conformational and temperature-sensitive stability defects of the delta F508 cystic fibrosis transmembrane conductance regulator in post-endoplasmic reticulum compartments. J Biol Chem 276, 8942-8950

68 M. Gentzsch (2004) Endocytic trafficking routes of wild type and DeltaF508 cystic fibrosis transmembrane conductance regulator. Mol Biol Cell 15, 2684-2696

69 J.P. Clement 4th (1997) Association and stoichiometry of K(ATP) channel subunits. Neuron 18, 827-838

70 N. Sharma (1999) The C terminus of SUR1 is required for trafficking of KATP channels. J Biol Chem 274, 20628-20632

71 E.A. Cartier (2001) Defective trafficking and function of KATP channels caused by a sulfonylurea receptor 1 mutation associated with persistent hyperinsulinemic hypoglycemia of infancy. Proc Natl Acad Sci U S A 98, 2882-2887

72 F. Yan (2004) Sulfonylureas correct trafficking defects of ATP-sensitive potassium channels caused by mutations in the sulfonylurea receptor. J Biol Chem 279, 11096-11105

73 F.F. Yan , J. Casey and S.L. Shyng (2006) Sulfonylureas correct trafficking defects of disease-causing ATP-sensitive potassium channels by binding to the channel complex. J Biol Chem 281, 33403-33413

74 V. Bernier , D.G. Bichet and M. Bouvier (2004) Pharmacological chaperone action on G-protein-coupled receptors. Curr Opin Pharmacol 4, 528-533

75 A. Ulloa-Aguirre (2006) G-protein-coupled receptor trafficking: understanding the chemical basis of health and disease. ACS Chem Biol 1, 631-638

76 J.P. Morello (2000) Pharmacological chaperones rescue cell-surface expression and function of misfolded V2 vasopressin receptor mutants. J Clin Invest 105, 887-895

77 J.A. Janovick , G. Maya-Nunez and P.M. Conn (2002) Rescue of hypogonadotropic hypogonadism-causing and manufactured GnRH receptor mutants by a specific protein-folding template: misrouted proteins as a novel disease etiology and therapeutic target. J Clin Endocrinol Metab 87, 3255-3262

78 S.M. Noorwez (2003) Pharmacological chaperone-mediated in vivo folding and stabilization of the P23H-opsin mutant associated with autosomal dominant retinitis pigmentosa. J Biol Chem 278, 14442-14450

79 U.E. Petaja-Repo (2002) Ligands act as pharmacological chaperones and increase the efficiency of delta opioid receptor maturation. Embo J 21, 1628-1637

80 J.M. Sands and D.G. Bichet (2006) Nephrogenic diabetes insipidus. Ann Intern Med 144, 186-194

81 J.P. Morello and D.G. Bichet (2001) Nephrogenic diabetes insipidus. Annu Rev Physiol 63, 607-630

82 S. Wuller (2004) Pharmacochaperones post-translationally enhance cell surface expression by increasing conformational stability of wild-type and mutant vasopressin V2 receptors. J Biol Chem 279, 47254-47263

83 A.H. Futerman and G. van Meer (2004) The cell biology of lysosomal storage disorders. Nat Rev Mol Cell Biol 5, 554-565

84 A.R. Sawkar , W. D'Haeze and J.W. Kelly (2006) Therapeutic strategies to ameliorate lysosomal storage disorders–a focus on Gaucher disease. Cell Mol Life Sci 63, 1179-1192

85 S. Ishii (1993) Characterization of a mutant alpha-galactosidase gene product for the late-onset cardiac form of Fabry disease. Biochem Biophys Res Commun 197, 1585-1589

86 T. Okumiya (1995) Galactose stabilizes various missense mutants of alpha-galactosidase in Fabry disease. Biochem Biophys Res Commun 214, 1219-1224

87 R. Kase (2000) Characterization of two alpha-galactosidase mutants (Q279E and R301Q) found in an atypical variant of Fabry disease. Biochim Biophys Acta 1501, 227-235

88 J.Q. Fan (1999) Accelerated transport and maturation of lysosomal alpha-galactosidase A in Fabry lymphoblasts by an enzyme inhibitor. Nat Med 5, 112-115

89 N. Asano (2000) In vitro inhibition and intracellular enhancement of lysosomal alpha-galactosidase A activity in Fabry lymphoblasts by 1-deoxygalactonojirimycin and its derivatives. Eur J Biochem 267, 4179-4186

90 G.H. Yam , C. Zuber and J. Roth (2005) A synthetic chaperone corrects the trafficking defect and disease phenotype in a protein misfolding disorder. Faseb J 19, 12-18

91 A.R. Sawkar (2002) Chemical chaperones increase the cellular activity of N370S beta-glucosidase: a therapeutic strategy for Gaucher disease. Proc Natl Acad Sci U S A 99, 15428-15433

92 A.R. Sawkar (2005) Gaucher disease-associated glucocerebrosidases show mutation-dependent chemical chaperoning profiles. Chem Biol 12, 1235-1244

93 J. Matsuda (2003) Chemical chaperone therapy for brain pathology in G(M1)-gangliosidosis. Proc Natl Acad Sci U S A 100, 15912-15917

94 M.B. Tropak (2004) Pharmacological enhancement of beta-hexosaminidase activity in fibroblasts from adult Tay-Sachs and Sandhoff Patients. J Biol Chem 279, 13478-13487

95 A. Frustaci (2001) Improvement in cardiac function in the cardiac variant of Fabry's disease with galactose-infusion therapy. N Engl J Med 345, 25-32

96 O. Polgar (2004) Mutational analysis of ABCG2: role of the GXXXG motif. Biochemistry 43, 9448-9456

97 S. Shukla (2003) Functional characterization of Candida albicans ABC transporter Cdr1p. Eukaryot Cell 2, 1361-1375

98 F. Buyse , M. Vandenbranden and J.M. Ruysschaert (2004) Mistargeted MRPdeltaF728 mutant is rescued by intracellular GSH. FEBS Lett 578, 145-151

99 T.W. Loo and D.M. Clarke (1998) Nonylphenol ethoxylates, but not nonylphenol, are substrates of the human multidrug resistance P-glycoprotein. Biochem Biophys Res Commun 247, 478-480

100 C.J. Partridge , D.J. Beech and A. Sivaprasadarao (2001) Identification and pharmacological correction of a membrane trafficking defect associated with a mutation in the sulfonylurea receptor causing familial hyperinsulinism. J Biol Chem 276, 35947-35952

101 K. Van Craenenbroeck (2005) Folding efficiency is rate-limiting in dopamine D4 receptorbiogenesis. J Biol Chem 280, 19350-19357

102 L. Valluru (2005) Ligand binding is a critical requirement for plasma membrane expression of heteromeric kainate receptors. J Biol Chem 280, 6085-6093

103 J.P. Fortin (2006) A nonpeptide antagonist reveals a highly glycosylated state of the rabbit kinin B1 receptor. Mol Pharmacol 69, 1146-1157

105 Z. Yu (2007) Isofagomine- and 2,5-anhydro-2,5-imino-D-glucitol-based glucocerebrosidase pharmacological chaperones for gaucher disease intervention. J Med Chem 50, 94-100

106 R.L. Lieberman (2007) Structure of acid beta-glucosidase with pharmacological chaperone provides insight into Gaucher disease. Nat Chem Biol 3, 101-107

107 G.D. Wiens , T. O'Hare and M.B. Rittenberg (2001) Recovering antibody secretion using a hapten ligand as a chemical chaperone. J Biol Chem 276, 40933-40939

108 C. Amat di San Filippo , M. Pasquali and N. Longo (2006) Pharmacological rescue of carnitine transport in primary carnitine deficiency. Hum Mutat 27, 513-523

109 B.E. Kim (2002) A conditional mutation affecting localization of the Menkes disease copper ATPase. Suppression by copper supplementation. J Biol Chem 277, 44079-44084

110 Z. Zhou , Q. Gong and C.T. January (1999) Correction of defective protein trafficking of a mutant HERG potassium channel in human long QT syndrome. Pharmacological and temperature effects. J Biol Chem 274, 31123-31126

111 B.A. Foster (1999) Pharmacological rescue of mutant p53 conformation and function. Science 286, 2507-2510

112 J.K. Chen (2002) Inhibition of Hedgehog signaling by direct binding of cyclopamine to Smoothened. Genes Dev 16, 2743-2748

113 R. Halaban (2001) Proper folding and endoplasmic reticulum to golgi transport of tyrosinase are induced by its substrates, DOPA and tyrosine. J Biol Chem 276, 11933-11938

C.R. Sanders and J.K. Myers (2004) Disease-related misassembly of membrane proteins. Annu Rev Biophys Biomol Struct 33, 25-51

N. Gregersen (2006) Protein misfolding and human disease. Annu Rev Genomics Hum Genet 7, 103-124

Recommend this journal

Email your librarian or administrator to recommend adding this journal to your organisation's collection.

Expert Reviews in Molecular Medicine
  • ISSN: -
  • EISSN: 1462-3994
  • URL: /core/journals/expert-reviews-in-molecular-medicine
Please enter your name
Please enter a valid email address
Who would you like to send this to? *


Full text views

Total number of HTML views: 3
Total number of PDF views: 24 *
Loading metrics...

Abstract views

Total abstract views: 180 *
Loading metrics...

* Views captured on Cambridge Core between September 2016 - 30th May 2017. This data will be updated every 24 hours.